- Home
- SYNX vs PHIO Comparison
SYNX vs PHIO Comparison
Compare SYNX & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYNX
- PHIO
- Stock Information
- Founded
- SYNX 2005
- PHIO 2011
- Country
- SYNX Israel
- PHIO United States
- Employees
- SYNX N/A
- PHIO N/A
- Industry
- SYNX
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- SYNX
- PHIO Health Care
- Exchange
- SYNX Nasdaq
- PHIO Nasdaq
- Market Cap
- SYNX 10.2M
- PHIO 12.1M
- IPO Year
- SYNX 2024
- PHIO N/A
- Fundamental
- Price
- SYNX $1.55
- PHIO $1.58
- Analyst Decision
- SYNX
- PHIO Strong Buy
- Analyst Count
- SYNX 0
- PHIO 3
- Target Price
- SYNX N/A
- PHIO $10.67
- AVG Volume (30 Days)
- SYNX 35.7K
- PHIO 8.3M
- Earning Date
- SYNX 09-26-2025
- PHIO 11-11-2025
- Dividend Yield
- SYNX N/A
- PHIO N/A
- EPS Growth
- SYNX N/A
- PHIO N/A
- EPS
- SYNX N/A
- PHIO N/A
- Revenue
- SYNX $6,003,000.00
- PHIO N/A
- Revenue This Year
- SYNX $32.35
- PHIO N/A
- Revenue Next Year
- SYNX N/A
- PHIO N/A
- P/E Ratio
- SYNX N/A
- PHIO N/A
- Revenue Growth
- SYNX N/A
- PHIO N/A
- 52 Week Low
- SYNX $1.37
- PHIO $0.97
- 52 Week High
- SYNX $6.49
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- SYNX 41.85
- PHIO 21.29
- Support Level
- SYNX $1.56
- PHIO $2.08
- Resistance Level
- SYNX $1.69
- PHIO $4.19
- Average True Range (ATR)
- SYNX 0.07
- PHIO 0.26
- MACD
- SYNX -0.01
- PHIO -0.06
- Stochastic Oscillator
- SYNX 22.45
- PHIO 2.61
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.